Heterocyclic Compounds

Matches 501 - 550 out of 36,928	< 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 >

Document	Document Title
WO/2023/233130A1	CD73 INHIBITOR COMPOUNDS The present invention relates to compounds of formula I shown below: wherein R1, X2, X3, X4, X5, X6, X7, X8 and X9 are each as defined in the application. The present invention also relates to processes for the preparation of these compo...
WO/2023/234425A1	AMINO ACID ACTIVE ESTER AND SALT THEREOF The present invention provides a novel active ester of an amino acid to be used for amino acylation of tRNA, said ester being capable of reducing risks to safety and waste. The present invention provides a compound represented by formula...
WO/2023/230541A1	PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.
WO/2023/226976A1	SIK INHIBITOR AND COMPOSITION THEREOF, METHOD FOR PREPARING SAME, AND USE THEREOF Disclosed are a compound represented by formula (I), and a racemate, a stereoisomer, a tautomer, an isotopic label, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof. The compound has a good SIK inhibition effect and ca...
WO/2023/230609A1	HETEROCYCLIC PAD4 INHIBITORS The disclosure generally relates to compounds of Formula I, comprising a 1,6,7,8-tetrahydro-5H-imidazo[4,5-g][1,6]isoquinolin-5-one moiety directly bonded to an azaindole or indole moiety, such compounds as inhibitors of PAD4, methods fo...
WO/2023/230542A2	PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
WO/2023/229430A1	HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF The present invention relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus can be effectively used as a therapeutic agent fo...
WO/2023/229346A1	NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME The present invention relates to: a novel compound for inhibiting nicotinamide phosphoribosyltransferase (NamPT); a composition including same; and various uses thereof.
WO/2023/229380A1	HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF The present invention relates to a heterocyclic compound, represented by chemical formula 1, exhibiting diacylglycerol kinase inhibitor activity, a pharmaceutical composition comprising same as an active ingredient, and a use thereof.
WO/2022/221227A9	AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS Disclosed are amino-substituted heteroaromatic compounds such as 4-amino-quinazolines, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing canc...
WO/2023/226902A1	PREPARATION METHOD FOR KRAS G12C INHIBITOR AND INTERMEDIATE THEREOF The present invention relates to a preparation method for a KRAS G12C inhibitor and an intermediate thereof. The method has a simple and efficient process route, low cost, low pollution and high safety and does not need column chromatogr...
WO/2023/227139A1	FUSED PYRIMIDINE DERIVATIVE AND APPLICATION THEREOF The invention relates to a novel fused pyrimidine compound as shown in general formula I, or a stereoisomer, pharmaceutically acceptable salt, solvate or prodrug thereof, and preparation methods and uses therefor. The meanings of R1, R2,...
WO/2023/226176A1	THIOAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF Disclosed in the present invention are thioamide derivatives having general formula (I), of which a structural formula is represented as [Formula I]. The present invention further provides a preparation method for said derivatives. The p...
WO/2023/230236A1	PROCESS FOR PREPARING JAK INHIBITORS AND INTERMEDIATES THEREOF The present disclosure relates generally to compounds which are useful as intermediates for the preparation of Janus kinase (JAK) inhibitors, and to processes for preparing the JAK inhibitors and intermediate compounds.
WO/2023/226965A1	ROCK INHIBITORS AND USES THEREOF Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as ROCK inhibitors. Also disclosed are pharmaceutical compositions comprising a compound of Formula (I), and methods of using s...
WO/2023/227867A1	HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 The present invention provides compounds of formula (I): 5 A 1 X Y N R 2 R 1 A 2 A 3 A 4 n Formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein R1, R2, n, A1, A2, A3, A4, X and Y are as defined in the...
WO/2023/226630A1	POLYMORPH OF KRAS INHIBITOR OR SALT THEREOF AND PREPARATION OF FORMULATION OF POLYMORPH Provided is a polymorph of a cycloalkyl and heterocycloalkyl inhibitor or a salt thereof. Specifically, the present invention relates to a polymorph of (S)-2-(4-(7-(8-chloro-7-fluoronaphthalen-1-yl)-2-(1-((dimeth ylamino)methyl)cycloprop...
WO/2023/229378A1	HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF The present invention relates to: a heterocyclic compound represented by chemical formula 1 and exhibiting diacylglycerol kinase inhibitor activity; a pharmaceutical composition comprising same as an active ingredient; and a use thereof.
WO/2023/227946A1	TYK2 INHIBITORS AND USES THEREOF Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
WO/2023/227052A1	BICYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF Disclosed herein are a compound represented by formula (II) or a stereoisomer, a pharmaceutically acceptable salt, a solvate, a co-crystal or a deuterated form thereof, or a pharmaceutical composition comprising same, and use thereof as ...
WO/2023/221721A1	SHP2 INHIBITOR AND USE THEREOF An SHP2 inhibitor, comprising a compound of formula (I), or a pharmaceutically acceptable salt, isomer, solvate, chelate, polymorph, acid, ester, metabolite or prodrug thereof. The present invention further relates to a pharmaceutical co...
WO/2023/222115A1	HYDROXYAMIDE DERIVATIVE AND USE THEREOF Provided in the present application is a hydroxyamide derivative represented by formula (I), and a tautomer, stereoisomer, solvate, metabolite, isotopically-labeled compound, pharmaceutically acceptable salt or co-crystal thereof. The co...
WO/2023/223174A1	COMPOSITIONS FOR PREVENTING OR TREATING IDIOPATHIC PULMONARY FIBROSIS (IPF) The present disclosure relates to a pharmaceutical composition for preventing or treating idiopathic pulmonary fibrosis, comprising a compound represented by formula I, optical isomers thereof or pharmaceutically acceptable salts thereof...
WO/2023/224853A1	AT2R ANTAGONISTS AND USES THEREOF This invention provides certain piperidine compounds as AT2R antagonists, e.g., compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof,...
WO/2023/225041A1	RIPK1 INHIBITORS AND METHODS OF USE Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related disea...
WO/2023/222762A1	N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF The present disclosure relates to proteolysis targeting chimeras (PROTACs) that modulate N6-adenosine-methyltransferase and methods of using the same.
WO/2023/222137A1	NOVEL TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND, AND USE THEREOF Provided are a novel tetrahydroisoquinoline compound, a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof. Specifically, provided are a nitrogen-containing heterocyclic compound as repr...
WO/2023/221078A1	SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT Crystalline forms of Compound I, active on URAT1, were prepared and characterized: Also provided are methods of using the crystalline forms.
WO/2023/222122A1	SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT Crystalline forms of Compound I, active on URAT1, were prepared and characterized: Also provided are methods of using the crystalline forms.
WO/2023/221900A1	SELECTIVE HER2 AND HER2 MUTATION INHIBITOR A selective HER2 inhibitor compound as shown in formula I or a pharmaceutically acceptable salt thereof.
WO/2023/223055A1	ANTI-VIRAL COMPOUNDS This invention relates to compounds that can be used to treat viral infections. The compounds of the present invention are papain-like protease (PLpro) inhibitors.
WO/2023/222084A1	BENZIMIDAZOLE OR AZABENZIMIDAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention are a benzimidazole or azabenzimidazole compound, a preparation method therefor and a use thereof. The benzimidazole or azabenzimidazole compound has a structure shown in formula (I). A use of the compo...
WO/2023/225252A1	COMPOSITIONS AND METHODS FOR INHIBITION OF RAS Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...
WO/2023/009833A9	MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for ex...
WO/2023/224998A1	INHIBITORS OF PARG Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease.
WO/2023/224981A1	HSD17B13 INHIBITORS AND USES THEREOF Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
WO/2023/221122A1	SALTS AND SOLID FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST The present disclosure provides solid and salt forms of an estrogen receptor (ER) inhibitor, compositions thereof and methods of treating a ER-mediated disorder.
WO/2023/225244A1	HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is ...
WO/2023/224413A1	HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING ELEMENT The present specification provides a heterocyclic compound, an organic light-emitting element comprising same, and a composition for an organic layer of an organic light-emitting element.
WO/2023/223188A1	PROCESS FOR THE PREPARATION OF FINERENONE AND INTERMEDIATES THEREOF The present invention relates to a process for the preparation of finerenone, a compound of formula I, and intermediates thereof. In particular, the present invention relates to a novel diastereomeric salt of an intermediate of finerenon...
WO/2023/222850A1	AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tr...
WO/2023/225001A1	NAPHTHYRIDINE BASED ENPP1 MODULATORS AND USES THEREOF The disclosure provides naphthyridines based on the ENPP1 modulators of Formula (I), (Ia), (Ib), (I-1), (I-1a), (I-1b), (I-2), (I-2a), (I-2b), or (Ic) and salts thereof, and their use for the modulation of ENPP1 activity.
WO/2023/217109A1	COMBINATION OF M6A RNA METHYLASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR FOR TREATING TUMORS A combination of a m6A RNA methylase inhibitor and an immune checkpoint inhibitor for treating tumors. The combination therapy is that the combination of a tumor immunotherapeutic agent and STM2457 or a derivative thereof is used for tre...
WO/2023/217230A1	KINESIN KIF18A INHIBITOR AND USE THEREOF The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
WO/2023/220129A1	BENZOYPARAZINE PYRAZINES ANE THEIR USES The present disclosure features compounds of Formula I, Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
WO/2023/220238A1	LRRK2 INHIBITORS The present invention relates to imidazo[4,5-c]quinoline compounds of Formula (I), and pharmaceutically acceptable salts thereof. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and t...
WO/2023/217045A1	FLUOROQUINOXALINONE DERIVATIVE FOR SELECTIVELY INHIBITING PARP1 Disclosed is a series of fluorine-substituted heterocyclic compounds, and specifically, disclosed are a compound represented by formula (XII) and a pharmaceutically acceptable salt thereof.
WO/2023/220402A1	ENPP1 MODULATORS AND PRODUCTS AND USES THEREOF Disclosed herein are compounds having the structure of Formula (I): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein A, Q1, R2, R3, Q4, R5, R6, R7, R and n are as defined he...
WO/2023/218195A1	GCN2 INHIBITORR The invention provides compounds of formula (I) Wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds...
WO/2023/218470A1	EFFICIENT PROCESS FOR PREPARATION OF APIXABAN HAVING CRYSTALLINE PARTICLES WITH D90 GREATER THAN 89 MICRON A cost-efficient process for the preparation of Apixaban of Formula I having crystalline particles size distribution D90 greater than 89 μm comprising insitu slow cooling crystallization without isolating crude making the said process o...

Matches 501 - 550 out of 36,928	< 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 >